retatrutide joint pain shows substantial weight loss and relief in obesity and OA patients | Andrew J. Sauer, MD posted on the topic Potential Retatrutide Benefits You Should

Open access funding provided by HEAL-Link Greece

The researchers says this body of evidence increases the need to study GLP-1 drugs as a potential approach to addressing persistent obesity in the US, which currently affects about 42 percent of the U.S

Willow offers GLP-1 medications, including Semaglutide and Tirzepatide, when determined by a doctor to be medically appropriate

While the results are still preliminary, these trials have shown improvements in abstinence and reductions in craving

Semaglutide typically shows noticeable appetite suppression within the first week and measurable weight loss within the first month

Those who took a placebo lost just 2.3% of their body weight